Acorda Therapeutics Sinks 13% On Discontinuation Of Drug For Post-stroke Walking

Acorda Therapeutics Sinks 13% On Discontinuation Of Drug For Post-stroke Walking


Acorda Therapeutics Inc. shares dropped as much as 13.2% in pre-market trade Monday after the company said it was discontinuing development of its drug intended for post-stroke walking difficulties after a clinical trial failure. Despite promising results for the drug dalfampridine in a phase 2 trial, the latest results were not sufficiently clinically meaningful, the company said.



from Biotech News